Catenae Innovation PLC says orders are starting to trickle in at its joint
The joint venture, renamed Synovate, has received orders from the sport of badminton’s governing body and “Lapland UK”, a Christmas destination event near Ascot
Catenae Innovation PLC (LON:CTEA) said its 50/50 joint venture with BHA-Medical, now renamed Synovate Global, has received its first orders.
One order is from the sport of badminton’s governing body and the other is for use at “Lapland UK”, a Christmas destination event near Ascot in Surrey.
Neither order will generate significant revenues but the orders do provide a commercial endorsement for Synovate’s offering, Catenae said.
“We are delighted to officially launch Synovate and to be able to provide commercial organisations with a comprehensive offering that they can use to test and securely manage COVID-19 cases within their corporations. Importantly, Synovate ensures that results from both Antigen and Antibody test are fed into PHE [Public Health England], where, in turn, they are inputted into the NHS’s ‘Test and Trace’ platform. Our platform is able to accept tests results from a range of differing testing procedures and is also able to accept an individual’s vaccination information,” said Guy Meyer, the chief executive officer of Catenae in a statement.
Meyer added that the company is experiencing increased interest in Synovate’s services from organisations across a range of industries.
Read More: Catenae Innovation PLC says orders are starting to trickle in at its joint